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HOXB7 encodes a transcription factor that is overexpressed in a number of cancers and encompasses many oncogenic func-
tions. Previous results have shown it to promote cell proliferation, angiogenesis, epithelial–mesenchymal transition, DNA
repair and cell survival. Because of its role in many cancers and tumorigenic processes, HOXB7 has been suggested to be a
potential drug target. However, HOXB7 binding sites on chromatin and its targets are poorly known. The aim of our study was
to identify HOXB7 binding sites on breast cancer cell chromatin and to delineate direct target genes located nearby these
binding sites. We found 1,504 HOXB7 chromatin binding sites in BT-474 breast cancer cell line that overexpresses HOXB7.
Seventeen selected binding sites were validated by ChIP-qPCR in several breast cancer cell lines. Furthermore, we analyzed
expression of a large number of genes located nearby HOXB7 binding sites and found several new direct targets, such as
CTNND2 and SCGB1D2. Identification of HOXB7 chromatin binding sites and target genes is essential to understand better the
role of HOXB7 in breast cancer and mechanisms by which it regulates tumorigenic processes.
HOX genes belong to a family of transcription factors called
homeobox genes that contain a 183-base-pair DNA region
named homeobox. This region encodes a 61-amino acid pro-
tein domain called homeodomain, which is able to bind to
DNA. Humans have 39 HOX genes organized in four chro-
mosomal clusters, A–D. These clusters of about 100 kb in
length are situated on different chromosomes: A at 7p14-15,
B at 17q21-22, C at 12q12-13 and D at 2q31-37. Each cluster
contains 9–11 HOX genes assigned to 13 paralogous groups
on the basis of their homeobox sequence similarities and
position within each cluster.1 HOX proteins play key roles in
the regulation of embryonal development and maintenance
of adult organ homeostasis. HOX gene expression is stage-
related and tissue- or region-speciﬁc, and it follows a unique
rule of temporal and spatial colinearity. The genes at the 30
end of the cluster are expressed ﬁrst and control the develop-
ment of anterior body parts, whereas genes at the 50 end are
expressed later during development and control more posterior
regions of the developing embryo.1–7 Because of their impor-
tant role in normal tissues, altered expression of HOX genes
has been observed in numerous cancers.1,8 HOXB7 is upregu-
lated in melanoma,9 leukemia,10 breast,11 lung,12 colorectal13
and pancreatic cancers,14 and it has a role in promoting cell
proliferation, angiogenesis,9,15–17 epithelial–mesenchymal tran-
sition (EMT),18 DNA repair and cell survival.19 Additionally,
HOXB7 has been observed to play a dual role in HER2-induced
breast cancer tumorigenesis by delaying tumor onset but pro-
moting metastatic tumor progression.20
Although all HOX proteins have DNA-binding homeodo-
mains, these domains do not determine binding speciﬁcity. It
has been observed that HOX proteins share a large homology
in amino acid sequence of their homeodomains, and these
domains bind to a very similar core sequence (TAAT) in
vitro. HOX transcription factors require cofactors for the
afﬁnity and speciﬁcity of binding to the target sites.21–23
HOX cofactors are proteins that bind to DNA cooperatively
with HOX proteins and help in selection of the proper bind-
ing site.24 The best known group of HOX cofactors is TALE
(three amino acid loop extension) proteins.25 These TALE
proteins in mammals are encoded by four Pbx genes (Pbx1,
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Pbx2, Pbx3 and Pbx4), three Meis genes (Meis1, Meis2 and
Meis3) and two Prep genes (Prep1 and Prep2). There are sev-
eral Pbx interaction domains in Hox proteins suggesting that
Hox–Pbx complexes may assemble onto cis-regulatory ele-
ments in several different ways depending on the target
gene.24 It has also been observed that the binding sites for
Hox–Pbx complex are often used for gene activation, whereas
sites with no clear Pbx input are used for both activation and
repression. This suggests that Hox–Pbx complexes would
recruit transcriptional co-activators rather than co-repressors.
Furthermore, it seems that Hox paralogs 1–5 use Pbx cofactors
more than paralogs 6–13 and that cis-regulatory elements
without Pbx input have several Hox binding sites. The same
cofactor directs different Hox proteins to different binding
sites suggesting that Hox protein contains the speciﬁcity infor-
mation, but it becomes revealed only in the presence of the
cofactor. HOXB7 is reported to require PBX1, PBX2 and
PREP1 cofactors for its oncogenic activity, and it also regulates
their expression.26 HOX collaborators are proteins that bind in
parallel to cis-elements of HOX proteins and determine
whether the target gene expression is activated or repressed
and the strength of this regulation.24 Multiprotein complexes
on cis-regulatory elements containing HOX proteins and their
cofactors and collaborators are called “Hoxasomes.”
We have previously found HOXB7 to be highly ampliﬁed
and overexpressed in breast cancer.11 In our study, our aim
was to delineate genome-wide chromatin binding sites of
HOXB7 in breast cancer using ChIP-seq and to identify
potential target genes that are directly regulated by this tran-
scription factor. This information is important in clarifying
the molecular basis and mechanisms of action behind its
oncogenic potential as well as in predicting the potential side
effects if using HOXB7 as a drug target.
Material and Methods
Human breast cancer cell lines and culture conditions
BT-474 ductal carcinoma, MCF7 adenocarcinoma, MDA-MB-
361 adenocarcinoma and T-47D ductal carcinoma cell lines
were purchased from ATCC (Manassas, VA). Dulbecco’s Modi-
ﬁed Eagle’s Medium for BT-474 was supplemented with 15%
Fetal Bovine Serum (FBS), 1% 100 mM sodium pyruvate, 1%
200 mM L-glutamine and 1% Pen-Strep (penicillin 10,000 U/ml,
streptomycin 10,000 mg/ml). Leibovitz’s L15 medium for MDA-
MB-361 was supplemented with 20% FBS, 1% 200 mM L-gluta-
mine and 1% Pen-Strep. Eagle’s Minimum Essential Medium
for MCF7 and RPMI-1640 for T-47D were supplemented with
10% FBS, 1% 200 mM L-glutamine and 1% Pen-Strep.
ChIP-seq
Fifty million BT-474 cells were used per sample, and chroma-
tin immunoprecipitation (ChIP) was performed according to
AffymetrixV
R
Chromatin Immunoprecipitation Assay Protocol.
Fifteen micrograms of HOXB7 antibody (Sigma-Aldrich, St.
Louis, MO) and normal rabbit IgG (Alpha Diagnostic Inter-
national, San Antonio, TX) were used for immunoprecipita-
tion. The ChIP-seq samples were prepared using NEBNext
DNA reagents according to the manufacturer’s protocol
(New England Biolabs, Ipswich, MA), and the DNA library
was sequenced using Illumina Genome Analyzer II. Four rep-
licates of IgG control were merged together and used as a
reference. From the four sequenced HOXB7 ChIP samples,
two and two samples were merged together to yield two bio-
logical replicates of HOXB7, which both contained approxi-
mately the same amount of reads as the IgG control data set.
The ChIP-seq data have been deposited to Gene Expression
Omnibus database with accession number: GSE47164.
Data analyses
ChIP-seq peak calling was performed using the MACS algo-
rithm27 with a p values cut-off of 1e205. The overlap analy-
sis, motif enrichment analysis and mapping of the binding
sites to nearest gene using a 630 kb window were performed
using Cistrome.28 The pathway analyses were performed with
WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt) using
KEGG, Wikipathways and Pathway Commons databases. The
gene ontology (GO) enrichment analyses were performed
with Chipster (http://chipster.csc.ﬁ/).
Correlation analysis
All microarray data were analyzed with the Anduril frame-
work,29 and all annotations were based on the Ensembl v70
with GRCh37. We downloaded gene expression microarrays
from The Cancer Genome Atlas for 522 primary breast carci-
noma tumors and 59 controls.30 First, probes matching either
multiple or no genes were removed. Then, the data were nor-
malized to a mean of 0. Each gene was assigned one of three
categories: upregulated, downregulated or normal. A gene
was considered upregulated if its expression was more than
three standard deviations over the median of normal samples.
Twelve samples displayed upregulation of HOXB7. To deter-
mine which of the genes that were located nearby the newly
found HOXB7 binding sites had an association with HOXB7
expression status, samples were divided into two groups
(HOXB7 upregulated and HOXB7 normal), and a signal-to-
What’s new?
The transcription factor HOXB7 is overexpressed in various cancers, but it’s not yet known just which genes HOXB7 activates.
How does it influence cancer on a molecular level? This study found 1500 sequences where HOXB7 binds the chromatin in
breast cancer cells. They went on to identify several potential target genes near the HOXB7 binding sites. Not only will finding
these genes help explain how HOXB7 overexpression promotes tumor growth, it will help understand what side effects might
result from hindering HOXB7 expression.
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noise statistic was calculated on the expression of each
gene.31 A p-value for each signal-to-noise score was calcu-
lated by a permutation test (1,000 permutations) and p-values
were corrected for multiple hypotheses using the Benjamini–
Hochberg procedure.
ChIP-qPCR
Five million cells were plated onto 150-mm dishes and cul-
tured for 4 days. Antibody conjugation and ChIP were per-
formed as described previously.32 Ten micrograms of HOXB7
antibody and normal rabbit IgG were used. The sites for vali-
dation were selected based on the following criteria: (i) strong
enrichment by ChIP-seq, (ii) location in proximal promoter or
(iii) location close to genes associated with epithelial cancers.
The primers for the binding sites were designed using Primer-
BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and
the sequences are listed in Supporting Information Table 1.
qPCR was carried out using LightCycler480 and SYBR Green I
detection system (Roche, Mannheim, Germany) according to
the manufacturer’s instructions. The enrichment of ChIP relative
to input chromatin was calculated using % input method and
the formula: 100*2(Adjusted input2Cp IP). Statistical signiﬁcance of
enrichment for HOXB7 vs. IgG was calculated using Student’s t-
test in SPSS or T.TEST in Excel. If the p-value was <0.05, the
result was regarded as statistically signiﬁcant.
Transductions
Five shRNA constructs targeting HOXB7 mRNA from the
MISSION
VR
RNAi library (Sigma-Aldrich) as well as controls,
including non-target shRNA and an empty pLKO-1 vector
were used. Lentiviral particles were produced at Biomedicum
Functional Genomics Unit (University of Helsinki, Finland).
One day before transductions, 100,000 BT-474 cells per well
were plated onto a 12-well plate. Next day, the medium was
changed, and 1 ml of polybrene and 500 ml of virus suspen-
sion were added to 500 ml of medium. The plate was incu-
bated at 378C for 10 min and then centrifuged at 2,500 rpm
for 30 min. After centrifugation, the plate was incubated at
378C for 6 hr after which the medium was changed. The
transduced cells were selected by puromycin treatment for a
week.
Immunoblotting
The cells were lysed in cold RIPA buffer (Sigma-Aldrich) supple-
mented with phosphatase and protease inhibitors (Thermo Fisher
Scientiﬁc, Waltham, MA and Roche, Basel, Switzerland, respec-
tively) and 1 mM Ethylenediaminetetraacetic acid. HOXB7 anti-
gen was detected with HOXB7 primary antibody (diluted in
1:250) and anti-rabbit secondary antibody (1:20,000) both from
Invitrogen (Camarillo, CA). The primary antibodies for CCND1
(Abcam, Cambridge, UK), EGFR, phospho-EGFR, AKT,
phospho-AKT, ERK, phospho-ERK, p38 and phospho p38 (Cell
Signaling, Boston, MA) were used at 1:1,000 dilution and incu-
bated overnight in 1% milk/TBS-Tween. Five to ten micrograms
of protein lysates were loaded on SDS-gels (BioRad, Hercules,
CA) and after electrophoresis, blotted to Polyvinylidene diﬂuo-
ride membranes with TurboTransferBlot equipment (BioRad,
Hercules). Membranes were blocked with 5% milk Tris Buffered
Saline with Tween for 1 hr and incubated with primary antibody
dilution (1% milk/Tris Buffered Saline with Tween (TBST),
1:1,000) overnight. Membranes were washed with TBST and
incubated with secondary antibody Horse radish Peroxidase-
goat-anti-rabbit or mouse IgG (H1 L; Invitrogen) in 1% milk/
TBST (1:20,000). Membranes were washed with TBST. Equal
protein loading was veriﬁed with a-tubulin primary antibody
(1:2,000, Sigma-Aldrich) and anti-mouse secondary antibody
(1:20,000, Invitrogen). Immobilon Western reagents (Millipore,
Billerica, MA) were used for chemiluminescence. Knockdown of
HOXB7 was quantiﬁed with ImageJ software, and alpha-tubulin
was used as a loading control.
RNA isolation and qRT-PCR
Total RNA was isolated using NucleoSpin RNA II kit
(Macherey-Nagel, D€uren, Germany) and transcribed to
cDNA using random hexamers supplied with SuperScriptTM
III First-Strand Synthesis System for RT-PCR (Invitrogen).
qPCR was carried out using LightCycler480 and SYBR Green
I detection system (Roche). Primer sequences of the genes
located nearby HOXB7 binding sites are shown in Supporting
Information Table 2. Each sample was measured in duplicate,
and the gene expression results were normalized using ACTB
mRNA levels as reference. The results were conﬁrmed using
also RPLPO mRNA levels as a reference (data not shown).
Results
Validation of HOXB7 antibody function
Two known genes, FGF29,15 and EGFR,33 have previously
been reported to possess HOXB7 binding sites nearby and to
be directly regulated by this transcription factor. We tested
ﬁrst whether HOXB7 antibody used for ChIP can recognize
these sites using following primers (50–30) for FGF2: forward
GTCATCTGTGGCACCTGCT and reverse AGATGAGGAT
GGGGATAAGGA and for EGFR: forward CAAGGCCAG
CCTCTGAT and reverse CCCCTTTCCCTTCTTTTGTT.
Strong enrichment was observed at both binding sites in sam-
ples immunoprecipitated with HOXB7 antibody as opposed to
those immunoprecipitated with non-speciﬁc IgG, thus validat-
ing the functionality of the selected HOXB7 antibody (Fig. 1).
ChIP-seq analysis of HOXB7 binding sites
We identiﬁed 1,504 new HOXB7 binding sites (false discov-
ery rate, FDR <5%) on BT-474 breast cancer cell chromatin.
Figure 2a contains examples of the binding sites representing
sites nearby C10orf10, ADORA2B and ABHD11 genes. Thirty
most enriched binding sites with an annotated nearest gene
are listed in Table 1, and the list encompassing all HOXB7
binding sites is shown in Supporting Information Table 3.
The majority of the binding sites are located at distal inter-
genic regions (52%) and introns (39%), and only 4% are situ-
ated at promoter regions (Fig. 2b).
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Motif and cis-element analyses of the HOXB7 binding sites
We performed de novo motif search to deﬁne a DNA
sequence that is enriched among the HOXB7 binding sites
on BT-474 cell chromatin. Figure 2c shows the most com-
mon motif that was present in 99.4% (1,496/1,504, z scores:
219.6898, p5 1e230) of the binding sites. We also deﬁned
the top-scoring cis-elements for the HOXB7 binding sites.
The top 15 cis-elements are shown in Supporting Informa-
tion Table 4. In addition, HOXB7 binding sites had hits to
known motifs of several other HOX transcription factors
(Supporting Information Table 5). For example, Hoxd1 and
HOXA3 motifs hit 97% of the found HOXB7 binding sites.
ChIP-qPCR validation of selected HOXB7 binding sites
Seventeen HOXB7 binding sites identiﬁed by ChIP-seq were
validated with ChIP-qPCR using a ChIP protocol different from
that for ChIP-seq. We ﬁrst validated the binding sites in two
breast cancer cell lines, BT-474 and MDA-MB-361, showing
high-level expression of HOXB7 (Fig. 3 and Supporting Infor-
mation Fig. 1). BT-474 shows high-level ampliﬁcation and
expression of HOXB7.11 In MDA-MB-361 cell line, HOXB7 is
highly expressed but not ampliﬁed. To further validate the bind-
ing sites, we included T-47D with intermediate HOXB7 expres-
sion as well as MCF7 with moderate expression of HOXB7
(Supporting Information Figs. 2 and 3). Enrichment was seen in
HOXB7 antibody versus IgG immunoprecipitated samples at all
the selected sites and in the vast majority of the cases the result
was statistically signiﬁcant (p< 0.05). Therefore, we conclude
that the 1,504 sites identiﬁed by ChIP-seq represent true chro-
matin binding sites of HOXB7 in breast cancer cells.
Correlation analysis in clinical breast cancer data
To see whether the genes located nearby HOXB7 binding sites
correlate with HOXB7 expression in clinical breast cancer data,
we compared the expression of these genes with HOXB7 in 12
HOXB7-overexpressing breast tumors to 510 normal tumors in
the breast cancer dataset of The Cancer Genome Atlas. We
found 37 positively and 27 negatively correlating genes
(q< 0.05) with HOXB7 expression (Supporting Information
Fig. 4 and Supporting Information Table 6), suggesting genes
potentially activated and repressed by HOXB7, respectively.
Expression of genes located nearby HOXB7 binding sites
BT-474 breast cancer cells were transduced with ﬁve different
lentiviral shRNA constructs targeting HOXB7 mRNA, but
only one construct resulted in a sufﬁcient knockdown of
HOXB7. The cells transduced with empty vector and non-
targeting shRNA construct were used as controls. Both
HOXB7 protein (Fig. 4a) and mRNA levels (Fig. 4b) were
decreased in cells transduced with HOXB7 shRNA construct
as compared to the controls. HOXB6 shares 40% homology
with HOXB7 and is expressed in BT-474 cell line. To test the
speciﬁcity of the HOXB7 shRNA construct, we determined its
effect also on HOXB6 expression, and no change in HOXB6
mRNA level was observed (Fig. 4c).
In order to examine whether the HOXB7 binding sites
were functional, the expression of nearby genes was analyzed
in HOXB7 depleted vs. control cells by measuring the levels
of encoded mRNAs with qRT-PCR. Altogether, 45 genes
nearby 31 binding sites were selected for further analysis.
These genes were chosen either because they were the nearest
genes of the binding sites or they were located nearby the
binding site and had been reported to be associated with
breast or some other epithelial tumor type. Eight genes,
SCGB1D1, SCGB1D2, SCGB1D4, SCGB2A1, SCGB2A2, DAP,
DHRS2 and ADORA2B, were found to be highly upregulated
(Fig. 5), whereas CCNB1, DFFA, NRL, TARDBP, PBX1 and
MAL2 showed moderate upregulation in HOXB7 knockdown
cells (Supporting Information Fig. 5). In addition, TRPC6
and ING3 were observed to be moderately upregulated and
correlated negatively with HOXB7 expression also in the clin-
ical breast cancer dataset of 12 HOXB7-overexpressing sam-
ples (The Cancer Genome Atlas). By contrast, APMAP,
CTNND2, DCAF11, EEF2K, PI3KR1 and WNT16 were mod-
erately downregulated in HOXB7-depleted cells (Fig. 5 and
Supporting Information Fig. 5). WNT16 correlated positively
with HOXB7 also in the clinical breast cancer data set
(p5 0.025, q5 0.154, Supporting Information Table 6).
Enriched pathways and GO categories among genes
located nearby the new HOXB7 binding sites
Pathways and GO categories enriched among genes located
nearby the HOXB7 binding sites are shown in Supporting
Information Tables 7 and 8, respectively. Enriched pathways
included, for example, pathways associated with FGF, EGFR
as well as MAPK signaling. Furthermore, enriched GO classes
were involved in the regulation of cell proliferation, transcrip-
tion, apoptosis and angiogenesis, supporting the previous
ﬁndings on HOXB7 function.
Effect of HOXB7 on regulation of signaling pathways
HOXB7 has been linked to enhanced cellular growth and
proliferation, and GO analysis showed enrichment of cellular
Figure 1. ChIP-qPCR validation of HOXB7 antibody in BT-474 breast
cancer cell line with two known binding sites located near FGF2
and EGFR genes. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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processes and pathways associated with these activities.
Therefore, it was imperative to study whether HOXB7 is
involved in regulating the activity of EGFR as well as down-
stream PI3K/AKT and MAPK signaling pathways, which are
the two critical pathways promoting cell growth and survival
in cancer. Interestingly, phospho-ERK protein levels
Figure 2. (a) Examples of the HOXB7 binding sites which are located close to annotated genes C10orf10, ADORA2B and ABHD11. (b) Distri-
bution of the HOXB7 binding sites between different genomic regions in BT-474 breast cancer cell line. (c) De novo motif search in BT-474
breast cancer cell line. The most enriched motif among the HOXB7 binding sites found with ChIP-seq.
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decreased upon HOXB7 knockdown, whereas AKT, p38
MAPK and EGFR signaling were activated when HOXB7 was
knocked down (Supporting Information Fig. 6).
Discussion
As HOX genes play key roles in regulating the homeostasis
of normal tissues and organs, deregulation of their expression
often results in serious consequences such as promotion of
oncogenic processes.1 Although the identiﬁcation of target
genes of HOX transcription factors is very essential, they still
remain largely uncovered. This is due to the fact that DNA
binding of different HOX proteins is highly similar in vitro
and they require a large amount of cofactors and collabora-
tors for binding speciﬁcity and direction of regulation
in vivo.24 This makes identiﬁcation of HOX targets very chal-
lenging. HOX proteins often share cis-elements with other
transcription factors and, therefore, it is unlikely that there
are targets that are speciﬁc for HOXB7 only. Based on
Table 1. Thirty most enriched new HOXB7 binding sites for which an annotated nearest gene was found
Chromosome Start End
Fold
enrichment Location
Nearest
gene Description
chr10 45474137 45474515 66,71 overlapStart C10orf10 Chromosome 10 open reading frame 10
chr17 15795989 15796350 50,83 Upstream ADORA2B Adenosine A2b receptor
chr5 151743562 151743627 49,79 Downstream NMUR2 Neuromedin U receptor 2
chr7 73160787 73161225 49,66 Upstream ABHD11 Abhydrolase domain containing 11
chr5 67845023 67845460 48,51 Downstream PIK3R1 Phosphoinositide-3-kinase,
regulatory subunit 1 (alpha)
chr16 30382250 30382612 46,4 Upstream TBC1D10B TBC1 domain family, member 10B
chr11 93398671 93398756 45,81 Inside KIAA1731 KIAA1731
chr6 4739139 4739232 45,11 Inside CDYL Chromodomain protein, Y-like
chr17 41499069 41499197 43,82 Downstream ARL4D ADP-ribosylation factor-like 4D
chr19 16895537 16895599 43,82 Upstream SIN3B SIN3 transcription regulator homolog B (yeast)
chr4 122694216 122694334 43,82 Upstream TMEM155 Transmembrane protein 155
chr12 8179103 8179513 43,2 Upstream FOXJ2 Forkhead box J2
chrX 48065011 48065133 42,51 Upstream SSX5 Synovial sarcoma, X breakpoint 5
chr15 76317972 76318114 41,83 Upstream NRG4 Neuregulin 4
chr3 52754097 52754183 41,83 Upstream GLT8D1 Glycosyltransferase 8 domain containing 1
chr4 118875392 118875509 41,83 Upstream NDST3 N-deacetylase/N-sulfotransferase
(heparan glucosaminyl) 3
chr5 67797322 67797381 41,83 Downstream PIK3R1 Phosphoinositide-3-kinase,
regulatory subunit 1 (alpha)
chr5 85485023 85485099 41,83 Upstream NBPF22P Neuroblastoma breakpoint family,
member 22, pseudogene
chrX 54447865 54448010 41,83 Upstream TSR2 TSR2, 20S rRNA accumulation,
homolog (S. cerevisiae)
chrX 119035398 119035530 41,83 Inside AKAP14 A kinase (PRKA) anchor protein 14
chr19 3723507 3723664 40,39 Inside TJP3 Tight junction protein 3
chr10 104133091 104133237 39,83 Upstream NFKB2 Nuclear factor of kappa light polypeptide
gene enhancer in B-cells 2 (p49/p100)
chr12 133489094 133489155 39,83 Inside PGAM5 Phosphoglycerate mutase family member 5
chr17 16806704 16806826 39,83 Downstream TBC1D27 TBC1 domain family, member 27
chr6 41330382 41330498 39,83 Downstream NCR2 Natural cytotoxicity triggering receptor 2
chr2 202144389 202144585 39,72 Inside CASP8 Caspase 8, apoptosis-related cysteine peptidase
chr19 4778968 4779146 39,6 Downstream MIR7-3 MicroRNA 7-3
chr19 5430778 5430841 38,4 Upstream ZNRF4 Zinc and ring finger 4
chr11 43335391 43335498 37,84 Inside API5 Apoptosis inhibitor 5
chr2 107095275 107095369 37,84 Upstream RGPD3 RANBP2-like and GRIP domain containing 3
The list of all 1,504 new binding sites of HOXB7 in BT-474 breast cancer cell line identified by ChIP-seq is shown in Supporting Information Table 3.
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studies with Drosophila, Mann et al.24 suggest that there are
three types of Hox target genes: (i) paralog-speciﬁc or genes
that are highly speciﬁc for one Hox paralog, (ii) semi-
paralog-speciﬁc or genes that are shared by a subset of Hox
proteins and (iii) general target genes of Hox proteins, which
are regulated by most or all Hox genes. Moreover, the bind-
ing sites of HOX transcription factors do not have to be
paralog-speciﬁc as long as the other genes using the same
sites are not expressed at the same time or in the same
tissues.
HOXB7 is overexpressed in many different cancers and is
associated with several oncogenic processes.12–18 We decided
to carry out pathway analysis to see whether our results are
in line with this data. For this analysis, we included all the
genes that were located close to HOXB7 binding sites. Our
assumption is that not all of these genes are directly regulated
by HOXB7, but the analysis is likely to highlight biological
processes that are important for HOXB7 regulation. We
identiﬁed several oncogenic pathways, such as EGFR, MAPK
and PI3K signaling, that were enriched among HOXB7 tar-
gets. Therefore, we wanted to test whether HOXB7 manipula-
tion has any impact on the activation of these pathways.
HOXB7 knockdown had moderate effect on AKT and p38
MAPK kinase signaling. On the other hand, HOXB7 knock-
down caused clear decrease in levels of ERK phosphorylation
as shown previously in colorectal and breast cancer.13,18 Sur-
prisingly, knockdown of HOXB7 showed increase in phos-
phorylated EGFR (Y1068) which is interesting, because
Y1068 is one of the phosphorylation sites for ERK activation.
Our data proposes that HOXB7 promotes activation of ERK,
but it could occur either through other tyrosine kinases than
EGFR or activation of threonine phosphorylation of
EGFR.34,35 Alternatively, ERK activation could result in feed-
back loop leading to inhibition of Y1068 of EGFR as well as
AKT signaling in BT-474.
HOXB7 has been suggested to be a potential drug target
due to its role in promoting cell proliferation and sur-
vival.12,14,33 However, very little is known about the HOXB7
binding sites on chromatin. In our study, we have identiﬁed
1,504 HOXB7 binding sites on BT-474 breast cancer cell
chromatin using ChIP-seq technique and validated these
results with ChIP-qPCR in four different breast cancer cell
lines. The vast majority of the binding sites were located at
distal intergenic regions and introns, suggesting that HOXB7
Figure 3. ChIP-qPCR validation of 17 HOXB7 binding sites on BT-474 breast cancer cell chromatin. The binding sites are named by the gene
nearest to the binding site. Results are averages of two biological replicates, which were done in duplicates. Statistical significance is
marked with an asterisk, p<0.05. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 4. Expression of HOXB7 in knockdown vs. control cells at (a) protein and at (b) mRNA levels in BT-474 breast cancer cell line. (c)
HOXB6 mRNA expression was not affected by HOXB7 shRNA. HOXB7 knockdown showed 45% of HOXB7 protein expression as compared to
100% in non-target cells in (a).
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mainly binds to distal enhancer regions. HOXB7 might regu-
late the expression of its target genes by interacting with the
basic transcriptional machinery through DNA looping rather
than binding to the promoter of its target gene itself. Similar
distribution of binding sites was seen with Hoxa2 in mouse
embryos.36 We studied expression of the genes located nearby
HOXB7 binding sites in a HOXB7 knockdown cell line and
clinical breast cancer samples. Correlation analysis for
HOXB7 and its potential target genes in publicly available
clinical breast cancer data revealed 64 genes of which 37 cor-
related positively and 27 correlated negatively with HOXB7
expression, suggesting direct target genes potentially activated
and repressed by HOXB7, respectively. Many of the targets
are suggested to have a role in breast cancer pathogenesis. To
name few, driver mutations were recently found on ARID1B
in breast cancer.37 LBH is a novel transcription co-factor and
a direct target of the WNT/b-catenin signaling pathway. It
was recently shown to be involved in the regulation of mam-
mary gland development and basal mammary stem cell line-
age.38 FOXJ2, which negatively correlated with HOXB7
expression, was shown to inhibit migratory properties of
human breast cancer.39
Interestingly, ﬁve genes from the secretoglobin gene fam-
ily, SCGB1D1, SCGB1D2, SCGB1D4, SCGB2A1 and
SCGB2A2, became highly upregulated upon HOXB7 knock-
down. These genes are located around a HOXB7 binding site
at 11q13 and seem to be repressed by HOXB7. SCGB1D1
and SCGB1D2 are also known as lipophilin A and lipophilin
B, respectively. These lipophilins form heterodimers with
SCGB2A proteins, for example, SCGB1D2 heterodimerizes
with SCGB2A2,40 and the heterodimers further associate to
form tetramers. SCGB1D4 has been reported to regulate che-
motactic migration and invasion,41 but the functions of other
members of the SCGB1D subfamily are still largely unknown.
SCGB2A1 and SCGB2A2 are also known as mammaglobins.
SCGB2A1 expression has been observed to be associated with
Figure 5. Deregulated expression of 12 genes located nearby HOXB7 binding sites in HOXB7 knockdown cells vs. empty vector and non-
target controls analyzed with qRT-PCR in BT-474 breast cancer cell line. [Color figure can be viewed in the online issue, which is available
at wileyonlinelibrary.com.]
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favorable outcome in ovarian cancer.42 Its role in breast can-
cer prognosis is still unknown, but in light of the published
data, it is interesting that SCGB2A1 potentially promoting
favorable outcome is suppressed by HOXB7. Two genes
around a binding site at 5p15, CTNND2 and DAP, showed
also a change in their expression upon HOXB7 depletion.
CTNND2 has been reported to be overexpressed in prostate
cancer and involved in tumor formation,43 making it an intrigu-
ing target activated by HOXB7. Furthermore, suppression of
DAP by HOXB7 is interesting due to its function as a potential
tumor-suppressor gene.44 HOXB7 has been reported to down-
regulate its cofactor PBX1,26 which was conﬁrmed also in our
study, because PBX1 became moderately upregulated after
HOXB7 suppression. Altogether, we were able to ﬁnd an expres-
sion change in 49% of the genes tested (22/45). This may be due
to the fact that HOXB7 requires cofactors and collaborators for
target gene regulation. Therefore, suppressing only HOXB7
expression may not be sufﬁcient to result in detectable expres-
sion changes in the majority of its target genes. Furthermore,
HOXB7 is part of the HOXB cluster located at 17q21-22, the site
that is ampliﬁed in 10% of primary breast cancers and in several
breast cancer cell lines,11 so when HOXB7 is overexpressed due
to this ampliﬁcation, as is the case in BT-474 cell line, several
other HOXB genes are also ampliﬁed and at least HOXB2 is also
overexpressed. It is not clear whether HOXB7 shares targets
with other HOXB genes, whereas functional redundancy has
been suggested for HOX genes belonging to the same paralo-
gous group.45 In this light, HOXB7 and HOXA7 could share
target genes if they are expressed in the same cell.
Although the signiﬁcance of HOXB7 overexpression has
been acknowledged in a number of cancers, the molecular
mechanisms behind its oncogenic potential are still largely
unknown. Our study reports >1,500 chromatin binding sites in
the genome of a breast cancer cell line overexpressing HOXB7.
The genes located nearby these binding sites are potential direct
targets of HOXB7. Only a handful of direct targets of HOXB7
have been published so far and therefore, our study provides
valuable data for further investigation. In the future, functional
studies of these genes are required to reveal speciﬁc mecha-
nisms through which HOXB7 executes its oncogenic potential.
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